Literature DB >> 18653742

Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance.

Chandra Prakash1, Weichao Chen, Michelle Rossulek, Kim Johnson, Chenghong Zhang, Thomas O'Connell, Michael Potchoiba, Deepak Dalvie.   

Abstract

The disposition of torcetrapib {(-)-[2R,4S] 4-[(3,5-bis-trifluoromethylbenzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester}, a cholesteryl ester transfer protein inhibitor, was studied in rats, monkeys, and mice after oral administration of a single dose of [14C]torcetrapib. Total mean recoveries of the radiocarbon were 90.9, 93.4, and 86.8% from mice, rats, and monkeys, respectively. Excretion of radioactivity was rapid and nearly complete within 48 h after dosing, with a majority excreted in the feces in all species. Torcetrapib was not detected in the urine and/or bile across species, suggesting that it is primarily cleared by metabolism in these species. More than 28 metabolites were identified in all species and were products of oxidation and conjugation pathways. The primary metabolic pathways of torcetrapib involved hydrolysis of the carbamate ester (M2) and the oxidation of the ethyl moieties. M2 was subsequently metabolized in parallel by oxidative cleavage to novel and unusual quinoline metabolites (M3, M4, M5, M9, and M17), M1 (bis trifluoromethyl benzoic acid), and M28 [3,5-bis(trifluoromethyl)phenyl-(methoxycarbonyl)methanesulfonic acid]. The structures of several metabolites were established by high-resolution liquid chromatography-tandem mass spectrometry and 1H NMR. The major circulating and excretory metabolites in mice, rats and monkeys were species-dependent; however, several common metabolites were observed in more than one species. In addition to parent torcetrapib, M1, M3, and M4 in rats, M4 and M17 in mice, and M3 and M8 in monkeys were detected as the major circulating metabolites. A mechanism for the formation of an unusual metabolite M28 has been proposed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18653742     DOI: 10.1124/dmd.108.022277

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  3 in total

1.  Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.

Authors:  Amir Hooshang Mohammadpour; Fatemeh Akhlaghi
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

2.  Metabolic profiling and population screening of analgesic usage in nuclear magnetic resonance spectroscopy-based large-scale epidemiologic studies.

Authors:  Ruey Leng Loo; Muireann Coen; Timothy Ebbels; Olivier Cloarec; Elaine Maibaum; Magda Bictash; Ivan Yap; Paul Elliott; Jeremiah Stamler; Jeremy K Nicholson; Elaine Holmes
Journal:  Anal Chem       Date:  2009-07-01       Impact factor: 6.986

3.  Use of bile correction factors for allometric prediction of human pharmacokinetic parameters of torcetrapib, a facile cholesteryl ester transfer protein inhibitor.

Authors:  Ramesh Mullangi; Preeti Ahlawat; Ravi K Trivedi; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jan-Mar       Impact factor: 2.569

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.